IL244380B - Compounds that inhibit or modulate the activity of kinases - Google Patents
Compounds that inhibit or modulate the activity of kinasesInfo
- Publication number
- IL244380B IL244380B IL244380A IL24438016A IL244380B IL 244380 B IL244380 B IL 244380B IL 244380 A IL244380 A IL 244380A IL 24438016 A IL24438016 A IL 24438016A IL 244380 B IL244380 B IL 244380B
- Authority
- IL
- Israel
- Prior art keywords
- kinases
- modulate
- inhibit
- activity
- compounds
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2013/068198 WO2015032423A1 (en) | 2013-09-03 | 2013-09-03 | Pharmaceutical compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
IL244380A0 IL244380A0 (en) | 2016-04-21 |
IL244380B true IL244380B (en) | 2018-01-31 |
Family
ID=49237179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL244380A IL244380B (en) | 2013-09-03 | 2016-03-02 | Compounds that inhibit or modulate the activity of kinases |
Country Status (12)
Country | Link |
---|---|
JP (1) | JP6239118B2 (ko) |
KR (1) | KR102191084B1 (ko) |
CN (1) | CN105793245B (ko) |
AU (1) | AU2013399913B2 (ko) |
BR (1) | BR112016004723B1 (ko) |
CA (1) | CA2941824C (ko) |
IL (1) | IL244380B (ko) |
MX (1) | MX369974B (ko) |
RU (1) | RU2652795C2 (ko) |
SG (1) | SG11201601503SA (ko) |
WO (1) | WO2015032423A1 (ko) |
ZA (1) | ZA201602047B (ko) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201617871D0 (en) | 2016-10-21 | 2016-12-07 | Sareum Limited | Pharmaceutical compounds |
WO2019132654A1 (en) * | 2017-12-27 | 2019-07-04 | Erasmus University Medical Center Rotterdam | Methods of treating sarcoidosis |
WO2020009566A1 (en) * | 2018-07-04 | 2020-01-09 | Erasmus University Medical Center Rotterdam | Methods of treating sarcoidosis |
GB201816369D0 (en) | 2018-10-08 | 2018-11-28 | Sareum Ltd | Pharmaceutical compounds |
BR112021021809A2 (pt) | 2019-04-30 | 2022-01-04 | Celgene Corp | Terapias de combinação compreendendo os inibidores de apremilast e tyk2 |
GB202005114D0 (en) | 2020-04-07 | 2020-05-20 | Sareum Ltd | Crystalline Forms of a Pharmaceutical Compound |
EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
EP4408527A2 (en) | 2021-09-30 | 2024-08-07 | Bristol-Myers Squibb Company | Methods for determining responsiveness to tyk2 inhibitors |
CA3236262A1 (en) | 2021-10-25 | 2023-05-04 | Isaac Marx | Tyk2 degraders and uses thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1497536A (en) * | 1973-12-17 | 1978-01-12 | Lilly Industries Ltd | 2-acylaminooxazoles methods for their preparation and their use |
EP1075467B1 (en) * | 1998-05-05 | 2005-03-30 | F. Hoffmann-La Roche Ag | Pyrazole derivatives as p-38 map kinase inhibitors |
GB0709031D0 (en) * | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
EP2166846B1 (en) | 2007-06-20 | 2012-10-17 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
WO2010011375A2 (en) | 2008-04-21 | 2010-01-28 | Merck & Co., Inc. | Inhibitors of janus kinases |
AU2009260389A1 (en) | 2008-06-18 | 2009-12-23 | Merck Sharp & Dohme Corp. | Inhibitors of Janus kinases |
JP2011527680A (ja) | 2008-07-09 | 2011-11-04 | メルク・シャープ・エンド・ドーム・コーポレイション | Janusキナーゼの阻害剤 |
EP2166006A1 (en) * | 2008-09-18 | 2010-03-24 | Dompe' S.P.A. | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
GB0820819D0 (en) * | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
CA2793024A1 (en) | 2010-03-17 | 2011-09-22 | F. Hoffmann-La Roche Ag | Imidazopyridine compounds, compositions and methods of use |
WO2012000970A1 (en) | 2010-07-01 | 2012-01-05 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
AU2012323399A1 (en) * | 2011-10-12 | 2014-05-29 | Array Biopharma Inc. | 5,7-substituted-imidazo[1,2-c]pyrimidines |
US20130231340A1 (en) * | 2012-03-02 | 2013-09-05 | Sareum Limited | Pharmaceutical compounds |
-
2013
- 2013-09-03 CN CN201380080517.XA patent/CN105793245B/zh active Active
- 2013-09-03 JP JP2016537144A patent/JP6239118B2/ja active Active
- 2013-09-03 BR BR112016004723-0A patent/BR112016004723B1/pt active IP Right Grant
- 2013-09-03 KR KR1020167007925A patent/KR102191084B1/ko active IP Right Grant
- 2013-09-03 MX MX2016002738A patent/MX369974B/es active IP Right Grant
- 2013-09-03 SG SG11201601503SA patent/SG11201601503SA/en unknown
- 2013-09-03 CA CA2941824A patent/CA2941824C/en active Active
- 2013-09-03 AU AU2013399913A patent/AU2013399913B2/en active Active
- 2013-09-03 WO PCT/EP2013/068198 patent/WO2015032423A1/en active Application Filing
- 2013-09-03 RU RU2016111522A patent/RU2652795C2/ru active
-
2016
- 2016-03-02 IL IL244380A patent/IL244380B/en active IP Right Grant
- 2016-03-29 ZA ZA2016/02047A patent/ZA201602047B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201602047B (en) | 2020-12-23 |
CA2941824A1 (en) | 2015-03-12 |
KR102191084B1 (ko) | 2020-12-15 |
KR20160048883A (ko) | 2016-05-04 |
MX2016002738A (es) | 2016-08-11 |
CN105793245B (zh) | 2018-03-20 |
BR112016004723A2 (ko) | 2017-08-01 |
AU2013399913B2 (en) | 2018-03-15 |
MX369974B (es) | 2019-11-27 |
AU2013399913A1 (en) | 2016-03-24 |
RU2016111522A (ru) | 2017-10-09 |
CN105793245A (zh) | 2016-07-20 |
CA2941824C (en) | 2020-08-25 |
SG11201601503SA (en) | 2016-03-30 |
RU2652795C2 (ru) | 2018-05-03 |
WO2015032423A1 (en) | 2015-03-12 |
BR112016004723B1 (pt) | 2022-08-30 |
JP6239118B2 (ja) | 2017-11-29 |
IL244380A0 (en) | 2016-04-21 |
JP2016529264A (ja) | 2016-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181296T1 (hr) | Novi spojevi za suzbijanje člankonožaca | |
IL243360A0 (en) | Methods for regulating the activity of cftr | |
HK1226073A1 (zh) | 凋亡信號調節激酶的抑制劑 | |
HK1212691A1 (zh) | 犬尿氨酸途徑的抑制劑 | |
IL244380B (en) | Compounds that inhibit or modulate the activity of kinases | |
EP2964221A4 (en) | COMPOUNDS INHIBITING THE ENZYMATIC ACTIVITY OF LEUKINE RICH REPETITION KINASE | |
EP3035800A4 (en) | Compounds inhibiting leucine-rich repeat kinase enzyme activity | |
EP2968347A4 (en) | MODULATORS OF THE EIF2ALPHA SIGNAL PATH | |
EP3019491A4 (en) | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | |
EP2964223A4 (en) | COMPOUNDS INHIBITING THE ENZYMATIC ACTIVITY OF KINASE WITH REPEATED PATTERNS RICH IN LEUCINE | |
EP2964222A4 (en) | COMPOUNDS FOR INHIBITING THE REPEATING ACTIVITY OF A LEUKINARY KINASEENZYME | |
IL244416A0 (en) | Antimicrobial compounds and methods for their preparation and use | |
EP2964220A4 (en) | COMPOUNDS INHIBITING THE ENZYMATIC ACTIVITY OF REPEATED SEQUENCE RICH IN LEUCINE | |
GB201316880D0 (en) | Controlling disclosure of structured data | |
EP3068389A4 (en) | Compounds inhibiting leucine-rich repeat kinase enzyme activity | |
GB2531878B (en) | Use of active noise system | |
EP2968995A4 (en) | INHIBITORS OF LRRK2 KINASE ACTIVITY | |
EP2952517A4 (en) | CONNECTION WITH REGULATORY ACTIVITY AGAINST A LYSOPHOSPHATIDYLSERIN RECEPTOR FUNCTION | |
IL258370A (en) | Oxa-diazaspiro compounds with analgesic activity | |
HK1222386A1 (zh) | 作爲詹納斯激酶的抑制劑的 -氰基甲基酰胺 | |
EP2959896A4 (en) | INHIBITOR OF PHOSPHORYLATION OF PROTEIN T | |
PT3365345T (pt) | Composto de oxa- azaespiro tendo atividade contra a dor | |
GB201323021D0 (en) | Use of kinase inhibitors | |
GB201321227D0 (en) | Use of kinase inhibitors | |
AU2013904907A0 (en) | Methods for the inhibition and dispersal of biofilms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed |